(Q36140676)

12 August 2017

1 reference

title

Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome (English)

1 reference

12 August 2017

2

Mona R Loutfy

1 reference

12 August 2017

Stephen Chihrin

1

1 reference

12 August 2017

publication date

1 April 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

3

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

251-262

1 reference

Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

SARS transmission, risk factors, and prevention in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Possible SARS coronavirus transmission during cardiopulmonary resuscitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Evidence of airborne transmission of the severe acute respiratory syndrome virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

SARS transmission among hospital workers in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

A major outbreak of severe acute respiratory syndrome in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

A comparative study of clinical features and outcomes in young and older adults with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Do men have a higher case fatality rate of severe acute respiratory syndrome than women do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Detection of SARS coronavirus in patients with suspected SARS

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Hepatitis C treatment update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Severe acute respiratory syndrome-associated coronavirus in lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Antiviral actions of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Treatment of hepatitis C virus: the first decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Interferons alpha and beta as immune regulators--a new look

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Interferon-beta 1a and SARS coronavirus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

A review of low-dose ritonavir in protease inhibitor combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Review article: glycyrrhizin as a potential treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Effect of hypoxia on vasodilator responses to S-nitroso-N-acetylpenicillamine and levcromakalim in guinea pig basilar artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Antimalarial Drug Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Corticosteroid therapy in severe illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Corticosteroids: the "terminator" of all untreatable serious pulmonary illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Short-term outcome of critically ill patients with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Avascular necrosis of bone in severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Use of convalescent plasma therapy in SARS patients in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

SARS: future research and vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Medicine. Caution urged on SARS vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.251

21 January 2018

Identifiers

DOI

10.1586/14787210.3.2.251

1 reference

12 August 2017

1 reference